Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages

C. Bartoloni, L. Guidi, R. Baroni, A. Tricerri, C. Barone, C. Garufi, G. Gambassi

Research output: Contribution to journalArticle

Abstract

CA 19-9 and CEA were serially assayed in 42 patients with gastrointestinal cancer at different stages: no evidence of disease (6 gastric and 7 colon cancer) on clinical follow-up, localized (3 hepatocarcinomas) and advanced disease (15 colon, 8 gastric and 3 pancreatic cancers) during chemotherapy. Increased levels of CA 19-9 alone predicted relapses in 2/7 patients with gastrointestinal cancer, while CEA did so in 3/7 and both markers increased in one patient before recurrence. In patients with advanced disease, both markers showed a trend to rise in the months prior to progression of metastasis. CEA was able to monitor the progression of disease with a sensitivity of 67%, while CA 19-9 had a sensitivity of 58% (p <0.01). However, the combined use of the two markers appears to slightly improve the sensitivity both in the post-surgical and in the advanced disease group; by means of the simultaneous assay, some information was added in 2/7 (28.6%) of post-surgical patients without evidence of disease, and in 2/36 (5.5%) of subjects bearing advanced cancer of the gastrointestinal tract. A little help in the management of such patients could therefore be obtained.

Original languageEnglish
Pages (from-to)351-362
Number of pages12
JournalJournal of Tumor Marker Oncology
Volume5
Issue number4
Publication statusPublished - 1990

Fingerprint

Gastrointestinal Neoplasms
Longitudinal Studies
Stomach Diseases
Recurrence
Pancreatic Neoplasms
Colonic Neoplasms
Disease Progression
Stomach
Colon
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bartoloni, C., Guidi, L., Baroni, R., Tricerri, A., Barone, C., Garufi, C., & Gambassi, G. (1990). Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages. Journal of Tumor Marker Oncology, 5(4), 351-362.

Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages. / Bartoloni, C.; Guidi, L.; Baroni, R.; Tricerri, A.; Barone, C.; Garufi, C.; Gambassi, G.

In: Journal of Tumor Marker Oncology, Vol. 5, No. 4, 1990, p. 351-362.

Research output: Contribution to journalArticle

Bartoloni, C, Guidi, L, Baroni, R, Tricerri, A, Barone, C, Garufi, C & Gambassi, G 1990, 'Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages', Journal of Tumor Marker Oncology, vol. 5, no. 4, pp. 351-362.
Bartoloni C, Guidi L, Baroni R, Tricerri A, Barone C, Garufi C et al. Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages. Journal of Tumor Marker Oncology. 1990;5(4):351-362.
Bartoloni, C. ; Guidi, L. ; Baroni, R. ; Tricerri, A. ; Barone, C. ; Garufi, C. ; Gambassi, G. / Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages. In: Journal of Tumor Marker Oncology. 1990 ; Vol. 5, No. 4. pp. 351-362.
@article{40d915eec3fd4c19885451e0ee9f6503,
title = "Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages",
abstract = "CA 19-9 and CEA were serially assayed in 42 patients with gastrointestinal cancer at different stages: no evidence of disease (6 gastric and 7 colon cancer) on clinical follow-up, localized (3 hepatocarcinomas) and advanced disease (15 colon, 8 gastric and 3 pancreatic cancers) during chemotherapy. Increased levels of CA 19-9 alone predicted relapses in 2/7 patients with gastrointestinal cancer, while CEA did so in 3/7 and both markers increased in one patient before recurrence. In patients with advanced disease, both markers showed a trend to rise in the months prior to progression of metastasis. CEA was able to monitor the progression of disease with a sensitivity of 67{\%}, while CA 19-9 had a sensitivity of 58{\%} (p <0.01). However, the combined use of the two markers appears to slightly improve the sensitivity both in the post-surgical and in the advanced disease group; by means of the simultaneous assay, some information was added in 2/7 (28.6{\%}) of post-surgical patients without evidence of disease, and in 2/36 (5.5{\%}) of subjects bearing advanced cancer of the gastrointestinal tract. A little help in the management of such patients could therefore be obtained.",
author = "C. Bartoloni and L. Guidi and R. Baroni and A. Tricerri and C. Barone and C. Garufi and G. Gambassi",
year = "1990",
language = "English",
volume = "5",
pages = "351--362",
journal = "Journal of Tumor Marker Oncology",
issn = "0886-3849",
publisher = "International Academy of Tumor Marker Oncology",
number = "4",

}

TY - JOUR

T1 - Longitudinal study of CA 19-9 and CEA in gastrointestinal cancer patients at different stages

AU - Bartoloni, C.

AU - Guidi, L.

AU - Baroni, R.

AU - Tricerri, A.

AU - Barone, C.

AU - Garufi, C.

AU - Gambassi, G.

PY - 1990

Y1 - 1990

N2 - CA 19-9 and CEA were serially assayed in 42 patients with gastrointestinal cancer at different stages: no evidence of disease (6 gastric and 7 colon cancer) on clinical follow-up, localized (3 hepatocarcinomas) and advanced disease (15 colon, 8 gastric and 3 pancreatic cancers) during chemotherapy. Increased levels of CA 19-9 alone predicted relapses in 2/7 patients with gastrointestinal cancer, while CEA did so in 3/7 and both markers increased in one patient before recurrence. In patients with advanced disease, both markers showed a trend to rise in the months prior to progression of metastasis. CEA was able to monitor the progression of disease with a sensitivity of 67%, while CA 19-9 had a sensitivity of 58% (p <0.01). However, the combined use of the two markers appears to slightly improve the sensitivity both in the post-surgical and in the advanced disease group; by means of the simultaneous assay, some information was added in 2/7 (28.6%) of post-surgical patients without evidence of disease, and in 2/36 (5.5%) of subjects bearing advanced cancer of the gastrointestinal tract. A little help in the management of such patients could therefore be obtained.

AB - CA 19-9 and CEA were serially assayed in 42 patients with gastrointestinal cancer at different stages: no evidence of disease (6 gastric and 7 colon cancer) on clinical follow-up, localized (3 hepatocarcinomas) and advanced disease (15 colon, 8 gastric and 3 pancreatic cancers) during chemotherapy. Increased levels of CA 19-9 alone predicted relapses in 2/7 patients with gastrointestinal cancer, while CEA did so in 3/7 and both markers increased in one patient before recurrence. In patients with advanced disease, both markers showed a trend to rise in the months prior to progression of metastasis. CEA was able to monitor the progression of disease with a sensitivity of 67%, while CA 19-9 had a sensitivity of 58% (p <0.01). However, the combined use of the two markers appears to slightly improve the sensitivity both in the post-surgical and in the advanced disease group; by means of the simultaneous assay, some information was added in 2/7 (28.6%) of post-surgical patients without evidence of disease, and in 2/36 (5.5%) of subjects bearing advanced cancer of the gastrointestinal tract. A little help in the management of such patients could therefore be obtained.

UR - http://www.scopus.com/inward/record.url?scp=0025643098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025643098&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025643098

VL - 5

SP - 351

EP - 362

JO - Journal of Tumor Marker Oncology

JF - Journal of Tumor Marker Oncology

SN - 0886-3849

IS - 4

ER -